Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
Heart Fail Clin
; 20(3): 333-341, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38844304
ABSTRACT
Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by the myocardial extracellular deposition of amyloid fibrils formed from the dissociation of TTR tetramer into monomers. The rate-limiting step in TTR amyloidogenesis is the dissociation of the TTR tetramer into monomers Tafamidis is an effective TTR-stabilizer in its native homotetrameric structure. Tafamidis is a safe and effective drug in reducing symptoms, hospitalization and mortality in accurately selected patients affected by hereditary and wild-type transthyretin amyloid cardiomyopathy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Benzoxazoles
/
Amyloid Neuropathies, Familial
/
Cardiomyopathies
Limits:
Humans
Language:
En
Journal:
Heart Fail Clin
Year:
2024
Document type:
Article